Myriad Genetics Inc operates in the Diagnostic substances sector. Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of the molecular diagnostic testing and analysis for its tests in its own reference laboratory. As of June 30, 2011, Myriad launched nine commercial molecular diagnostic tests. Myriad's commercial molecular diagnostic tests included BRACAnalysis, COLARIS, COLARIS AP, MELARIS, OnDose, PANEXIA, PREZEON, Prolaris and TheraGuide. Its molecular diagnostic tests include five predictive medicine, three personalized medicine and one prognostic medicine test. The Company's companion diagnostic services consist of Multi-Analyte Profile (MAP), Multiplexed Immunoassay Kits and TruCulture. On May 31, 2011, Myriad acquired Rules-Based Medicine, Inc., which is operating as Myriad RBM, Inc. (Myriad RBM). In our complete report available for purchase the company is compared to: Immucor, Inc., Biomarin Pharmaceutical Inc and Nature's Sunshine Products, Inc.